Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop in dramatic fashion. After its twelve-week trial, Tonmya, a drug that treats military-related post-traumatic stress disorder (PTSD), showed “inadequate separation from placebo.”.
Should you buy Tonix Pharmaceuticals (Tonix) stock?
1 day ago · So what. For its first quarter, Tonix -- a pre-revenue biotech -- posted a net loss of $26.7 million, or $0.05 per share. This was deeper than …
Is Tonix Pharmaceuticals's P/E ratio good or bad?
Apr 29, 2022 · Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What are the Technical Signals for Tonix Pharmaceuticals Holding (Tonix)?
Feb 08, 2021 · Now what. Tonix also announced a stock offering on Monday. The biotech will sell approximately 58.3 million shares to investors at a price …
What is happening with Tonix Pharmaceuticals Holding Corp (TMP) stock?
Sep 29, 2014 3:27 PM EDT NEW YORK ( TheStreet) -- Shares of Tonix Pharmaceuticals ( TNXP) - Get Tonix Pharmaceuticals Holding Corp. Report plummeted 49.43% to …
Is tonix Pharmaceuticals a good stock to buy?
Will tonix Pharmaceuticals stock go up?
Will Tonix reverse split?
What happened to Tonix Pharmaceuticals stock in 2016?
What is the ticker symbol for Tonix Pharmaceuticals?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
How many shares of Tonix Pharmaceuticals are there after the split?
The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
When did Tonix Pharmaceuticals reverse split?
Tonix Pharmaceuticals's stock reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
Where is Tonix Pharmaceuticals located?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY , 10022. The company can be reached via phone at (212) 980-9155, via email at [email protected], or via fax at 212-923-5700.
Does Tonix pay dividends?
Tonix Pharmaceuticals does not currently pay a dividend.
Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Tonix Pharmaceuticals Holding Corp.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Tonix Pharmaceuticals Holding Corp. stock A Buy?
Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Tonix Pharmaceuticals Holding Corp
In the last 100 trades there were 20.56 million shares bought and 10 thousand shares sold. The last trade was done 8 days ago by Lederman Seth who bough 5 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
The biotech wants to help doctors measure T-cell immunity to the novel coronavirus
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Tonix Pharmaceuticals ( NASDAQ:TNXP) jumped 22% on Monday after the biopharmaceutical company said it would develop a COVID-19 skin test.
So what
Tonix intends to develop a diagnostic skin test, called TNX-2100, to measure T-cell immunity to SARS-CoV-2, the virus that causes COVID-19. Researchers believe T-cell immunity can help protect against severe forms of the disease.
Now what
Tonix also announced a stock offering on Monday. The biotech will sell approximately 58.3 million shares to investors at a price of $1.20 per share. Tonix expects to raise roughly $70 million, which it can use to fund the development of TNX-2100 and other clinical studies.
Where is Tonix Pharmaceuticals located?
Tonix Pharmaceuticals is based in New York and specializes in producing drugs that treat specific central nervous system conditions. “These results underscore the challenges in designing and conducting well-controlled clinical studies in PTSD, especially military-related PTSD.
How long did the Tonmya trial last?
After its twelve-week trial, Tonmya, a drug that treats military-related post-traumatic stress disorder (PTSD), showed “inadequate separation from placebo.”
Why do companies have a rough start in the stock market?
Good companies often have a rough start in the stock market, because there are as many people who do not believe in the idea and wants to stay away or bet against it. It is very common to see 50-70% drop from my initial buy price before i start to see the real difference. Secondly, the company will not give away great result in the form of media release until they have all their vested partners invested fully on it. This takes a lot of time and confirmation to ensure everyone has gotten a good entry point.
What is TNX 3500?
TNX-3500 product candidate, is a potent antiviral against SARS-CoV-2, the cause of COVID-19, and suppresses viral replication in tissue culture with greater efficacy than remdesivir, the active pharmaceutical ingredient of Gilead Sciences.
Is Tonix blinded?
Tonix remains blinded to the detailed interim analysis results and only received the recommendation made by the IDMC. Preliminary blinded safety data from these participants did not reveal any new safety signals, and the decision to discontinue enrolling new participants is not related to safety.
Is Tonix a biopharmaceutical company?
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to support the initiation of a Phase 2 study of TNX-1900* (intranasal potentiated oxytocin) for the prevention of migraine headache in chronic migraineurs. The program is expected to qualify for the 505 (b) (2) pathway for FDA approval, which is available to new formulations of an approved drug.
Will Gilead buy out Tonix?
Gilead may buyout Tonix if Sangivamycin as it is highly effective against SARS-CoV-2 in vitro and has favorable drug properties to replace Remdesivir.
Is AXSM the same as TNXP?
If you compare AXSM with TNXP you can see that they both are very similar. Neither have a product on the market but AXSM is very close. I have invested long term in both companies, but I believe the greatest potential is here with TNXP mostly due to its highly undervalued share price. Happy Thanksgiving everyone!!!
Is Tonix ready for the big jump?
Tonix is getting ready for the big jump !!! They are going to make the best vaccine on the market.
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares rose 56.1% to $24.41 in pre-market trading after UCB announced plans to acquire the company.
18 Stocks Moving in Monday's Pre-Market Session
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday.
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rose 33.6% to $3.10 in pre-market trading. BiondVax reported successful closing of $9.8 million follow-on underwritten offering of ADSs including exercise of the over-allotment.
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results were down year over year.
